Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

被引：3
|
作者：
Hess, Georg [1 ]
Karola, Wagner [2 ]
LaRosee, Paul [3 ]
Keller, Ulrich [4 ]
Atta, Johannes [5 ]
Witzens-Harig, Mathias [6 ]
Crombe, Anne [7 ]
Medler, Christoph [8 ]
Borchmann, Peter [9 ,10 ]
Bitz, Ulrich [11 ]
Lerchenmuller, Christian [12 ]
Theobald, Matthias [1 ]
Dreyling, Martin H. [13 ]
机构：
[1] Johannes Gutenberg Univ Med Ctr, III Dept Med, Mainz, Germany
[2] Charite, Gerlingen, Germany
[3] Jena Univ Hosp, Jena, Germany
[4] Tech Univ Munich, Munich, Germany
[5] Goethe Univ Frankfurt, Frankfurt, Germany
[6] Univ Heidelberg Hosp, Dept Internal Med V, Heidelberg, Germany
[7] Univ Mainz Hosp, Interdisciplinary Ctr Clin Trials IZKS, Mainz, Germany
[8] IZKS, Mainz, Germany
[9] Univ Hosp Cologne, Dept I Internal Med, Cologne, Germany
[10] Univ Hosp Cologne, German Hodgkin Study Grp GHSG, Cologne, Germany
[11] HELIOS Klin Bad Saarow, Bad Saarow Pieskow, Germany
[12] Outpatient Clin, Hematol & Oncol, Munster, Germany
[13] Univ Hosp Grosshadern LMU, Dept Med III, Munich, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2977.2977
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2977
引用
收藏
页数：4
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF BORTEZOMIB AND RITUXIMAB ASSOCIATION IN RELAPSED/REFRACTORY INDOLENT NON-FOLLICULAR AND MANTLE CELL LYMPHOMA: FINAL RESULTS OF PHASE II STUDY BY INTERGRUPPO ITALIANO LINFOMI
    Chiappella, A.
    Pregno, P.
    Zinzani, P. L.
    Evangelista, A.
    Fabbri, A.
    Facchetti, F.
    Ferreri, A.
    Franceschetti, S.
    Freilone, R.
    Gargantini, L.
    Gioia, D.
    Liberati, A. M.
    Orsucci, L.
    Rigacci, L.
    Russo, E.
    Stefoni, V.
    Tucci, A.
    Vitolo, U.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 106 - 107
  • [32] RITUXIMAB PLUS SARGRAMOSTIM FOR THE TREATMENT OF NEWLY DIAGNOSED FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE II STUDY
    Fowler, N.
    Mclaughlin, P.
    Fisch, M.
    Dakhil, S.
    Bury, M.
    Fayad, L.
    Shah, J.
    Neelapu, S.
    Romaguera, J.
    Rodriguez, D.
    Ayala, A.
    Kwak, L.
    ANNALS OF ONCOLOGY, 2011, 22 : 187 - 187
  • [33] The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Friedberg, Jonathan W.
    Vose, Julie M.
    Kelly, Jennifer L.
    Young, Faith
    Bernstein, Steven H.
    Peterson, Derick
    Rich, Lynn
    Blumel, Susan
    Proia, Nicole K.
    Liesveld, Jane
    Fisher, Richard I.
    Armitage, James O.
    Grant, Steven
    Leonard, John P.
    BLOOD, 2011, 117 (10) : 2807 - 2812
  • [34] Radioimmunotherapy with 131I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma
    Jang, Yoon Jung
    Lim, Sang Moo
    Lee, Inki
    Byun, Byung Hyun
    Lim, Ilhan
    Kim, Byung Il
    Choi, Chang Woon
    Lee, Seung-Sook
    Suh, Cheolwon
    Yoon, Dok Hyun
    Kim, Inho
    Nam, Seung-Hyun
    Lee, Mark Hong
    Won, Jong Ho
    Kong, Jee Hyun
    Jeong, Seong Hyun
    Oh, Suk Joong
    Park, Keon Woo
    Han, Jae Joon
    Song, Moo-Kon
    Yang, Sung Hyun
    Na, Im Il
    Lee, Hyo-Rak
    Shin, Dong-Yeop
    Kang, Hye Jin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (06) : 690 - 696
  • [35] Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
    Inwards, D. J.
    Fishkin, P. A.
    LaPlant, B. R.
    Drake, M. T.
    Kurtin, P. J.
    Nikcevich, D. A.
    Wender, D. B.
    Lair, B. S.
    Witzig, T. E.
    ANNALS OF ONCOLOGY, 2014, 25 (10) : 2020 - 2024
  • [36] Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma
    Inwards, David J.
    Fishkin, Paul
    LaPlant, Betsy R.
    Drake, Matthew T.
    Kurtin, Paul
    Nikcevich, Daniel
    Wender, Donald
    Lair, Bradley
    Witzig, Thomas E.
    BLOOD, 2012, 120 (21)
  • [37] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
    R Sakai
    K Ohmachi
    F Sano
    R Watanabe
    H Takahashi
    H Takasaki
    M Tanaka
    Y Hattori
    H Kimura
    M Takimoto
    T Tachibana
    E Tanaka
    Y Ishii
    Y Ishiyama
    M Hagihara
    K Miyazaki
    K Yamamoto
    N Tomita
    K Ando
    Annals of Hematology, 2019, 98 : 2131 - 2138
  • [38] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
    Baiocchi, Robert A.
    Alinari, Lapo
    Lustberg, Mark E.
    Lin, Thomas S.
    Porcu, Pierluigi
    Li, Xiaobai
    Johnston, Jeffrey S.
    Byrd, John C.
    Blum, Kristie A.
    CANCER, 2011, 117 (11) : 2442 - 2451
  • [39] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
    Sakai, R.
    Ohmachi, K.
    Sano, F.
    Watanabe, R.
    Takahashi, H.
    Takasaki, H.
    Tanaka, M.
    Hattori, Y.
    Kimura, H.
    Takimoto, M.
    Tachibana, T.
    Tanaka, E.
    Ishii, Y.
    Ishiyama, Y.
    Hagihara, M.
    Miyazaki, K.
    Yamamoto, K.
    Tomita, N.
    Ando, K.
    ANNALS OF HEMATOLOGY, 2019, 98 (09) : 2131 - 2138
  • [40] HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
    Stevens, Wendy B. C.
    Bakunina, Katerina
    Cuijpers, Marloes
    Chamuleau, Martine
    Beeker, Aart
    Fijnheer, Rob
    Hebart, Holger
    Visser, Hein P. J.
    Doorduijn, Jeanette K.
    Linton, Kim
    Dreyling, Martin
    de Jong, Daphne
    Kersten, Marie Jose
    HEMASPHERE, 2020, 4 (01):
12345